Company intelligence / Profile preview

Mercalis

Morrisville, North Carolina, United Statespolicyreporter.com ↗

Ownership: Private
Development stage: Commercial

Overview

Mercalis was an integrated life sciences commercialization partner providing end-to-end solutions across the biopharmaceutical value chain, including consulting, market access intelligence, patient support services, and healthcare provider engagement. In recent years it expanded rapidly through organic growth and acquisitions, rebranding from TrialCard in September 2023. By the end of 2024 it had partnerships with most top global pharmaceutical companies and supported millions of patients through its programs. In March 2025 it merged with PharmaCord to form Valeris[3][4][6][7].

Therapeutic areas: OncologyRare DiseasesNeurology
Industry: Consulting

Partnerships

19 out of top 20 global pharmaceutical companies by year-end 2024

Beyond the preview

Go deeper on Mercalis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mercalis.

Explore the full profile